Professor Andreas Hougaard Laustsen-Kiel. Photo: DTU.
Prototype treatment for snake bite envenoming proves effective against the venom of African and Asian elapid snakes, such as some cobra, mamba, and krait species, new research shows.
Snakes bite 5.4 million people each year—and roughly half are injected with venom, according to the WHO. Between 81,000 and 138,000 people die, while around three times as many suffer amputations and other permanent disabilities. Due to their size, children often suffer the most severe effects.
For 128 years, our primary treatment against snakebite has been using mixtures of polyclonal antibodies derived from immunized animal blood. Although they are proven effective, these medicines may cause adverse reactions that can sometimes be severe. So, the search for novel ways to treat severe snakebite envenoming is ongoing.
Recently, an international team of scientists led by DTU reached remarkable results and developed a new modernized prototype treatment that proves effective against the venom of African and Asian elapid snakes, such as some cobra, mamba, and krait species—many of which are among the world’s deadliest.
“We have previously developed antibodies against the venom toxins from single snake species; however, our new results demonstrate that our technology has great potential in neutralizing toxins from multiple species, even from different continents. This broadened cross-neutralization capacity is very promising. It could provide the basis for more effective treatments for snakebite victims in the future,” says Andreas Hougaard Laustsen-Kiel, a professor at DTU Bioengineering.
He conducted the research with colleagues at DTU, ETH Zurich, Universidad de Costa Rica, and industrial partners Sophion Bioscience and IONTAS. Their work is published in Nature Communications.
New antibody works against several neurotoxins
In essence, their approach is to develop antibodies of fully human origin, which offer fewer adverse reactions, competitive costs, and, when fine-tuned, superior efficacy. They use phage display technology, a popular in vitro methodology within drug discovery, to select antibodies that bind well to the toxins in the venom, enabling broad neutralization.
“There has been a revolution in recombinant antibody technology over the last three decades. I am delighted to be involved in these efforts to direct phage display technology to the blight of snakebite envenomation,” says John McCafferty, the inventor of antibody phage display. He founded IONTAS and has recently established a new anti-venom group at the University of Cambridge.
Deliberately selecting hundreds of antibody candidates and testing the most promising against toxins in different snake venoms, the researchers found that one in particular (2554_01_D11) was especially potent and broadly neutralizing. It bound to various neurotoxins present in the venoms of the monocled cobra, the forest cobra, the spectacled cobra, the king cobra, the black mamba, and the many-banded krait.
Subsequent in vivo studies showed that the antibody prevented or delayed death from venom. For the monocled cobra specifically, the antibody completely prevented lethality in envenomed mice.
“In light of the positive results regarding the neutralization of venom from the monocled cobra, we mimicked a true rescue situation, injecting mice with cobra venom and then administering the antibody. And sure enough, we were able to prevent death when the antibody was injected rapidly after envenoming”, says José María Gutiérrez, emeritus professor of Instituto Clodomiro Picado, University of Costa Rica.
While the antibody could not prevent death from black mamba venom, survival was prolonged by several hours, suggesting that the antibody provided a partial neutralization of the venom.
“These are remarkable results,” says Andreas Hougaard Laustsen-Kiel:
“The antibody we used worked against different neurotoxins derived from different snake species from different parts of the world. These toxins are far from identical but share some crucial similarities in their structure. And apparently, these are just enough for our antibody to display extensive cross-reactivity. We have yet to establish the boundaries of what this antibody can neutralize. Still, we would like to see if it shows the same promise concerning neurotoxins from, for example, the blue krait, the banded krait, and the Egyptian cobra.”
The researchers expect antibodies, such as 2554_01_D11, will be helpful when designing future envenoming therapies. At the same time, however, they stress that their pipeline for discovery could be useful in developing other broadly neutralizing antibodies against toxins from other animals, bacteria, viruses, and parasites or even in developing cancer therapies.
Original Article: New human antibody neutralizes snake neurotoxins across species and geographies
More from: Technical University of Denmark | ETH Zürich
The Latest Updates from Bing News
Go deeper with Bing News on:
Recombinant antibody technology
- Global Recombinant DNA Technology Market Report 2023: Increasing Number of Chronic Diseases Drives Growth
The "Recombinant DNA Technology Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and ...
- Y-mAbs’ Danyelza injection receives marketing approval in Brazil
Y-mAbs has received marketing authorisation for Danyelza (naxitamab-gqgk) 40mg/10mL injection from the Brazilian Health Regulatory Agency ...
- Global Custom Antibody Market Report to 2030: Increasing Demand for Customized Diagnostics and Therapeutics Drives Growth - ResearchAndMarkets.com
The global custom antibody market size is expected to reach USD 301.7 million by 2030, expanding at a CAGR of 9.7% from 2023 to 2030. The market is expected to witness substantial growth during the ...
- Rabbit Monoclonal Antibody: a New Diagnostics Technology
However, a new technology for generating rabbit monoclonal antibodies ... or the hybridoma IgG gene is cloned and recombinant antibody is produced in a mammalian expression system. unexpectedly with ...
- Antibody–drug conjugates: a novel paradigm for cancer therapy
However, these antibodies elicited a significant immune response, resulting in reduced therapeutic efficacy. With the advent of recombinant technology, mouse antibodies have been replaced with ...
Go deeper with Bing News on:
- How to Prepare for Your First Physical Therapy Session
How to Prepare for Your First PT Session If a doctor has told you that physical therapy could help you and you’ve never had it before, you probably have some questions about what to expect from ...
- Balancing Efficacy and Toxicity of Novel Therapies in Systemic Lupus Erythematosus
Table 1. Monitoring of systemic lupus erythematosus patients who receive immunosuppressive or biologic therapies. Drug Potential toxicity Monitoring Cyclophosphamide Myelosuppression ...
- Occupational Therapy Assistant
Occupational therapy assistants help people facing physical or mental challenges gain or regain the skills necessary for their highest quality of life. This can involve everything from daily tasks ...
- Best Online Therapy Services Of May 2023
American Psychiatric Association. Accessed 06/28/2022. . If you’re interested in options for online therapy, Forbes Health has rounded up our top picks to help make your search easier.
- Talk Therapy: What It Is, Types And Effectiveness
National Alliance on Mental Illness. Accessed 11/3/2022. . Talk therapy, also known as psychotherapy, involves a person meeting with a therapist in a confidential environment to speak about their ...